Aplagon is a private pharmaceutical development company focused on addressing unmet patient needs associated with vascular injury related thrombotic blood vessel occlusions and subsequent organ damage.

LOCALLY ACTING VASCULOPROTECTIVE ANTITHROMBOTICS

APAC PRODUCTS

Aplagon is developing APACs, biological mimetics of heparin proteoglycans, as potent, first-in-class antithrombotic and vasculoprotective products for the clinical management of vascular injury related thrombotic blood vessel occlusions leading to organ damage. The initial clinical target indications include hemodialysis access failure, COVID-19/sepsis-induced coagulopathy and peripheral arterial disease, where there is significant unmet medical need.

APAC MULTIPLE MECHANISMS OF ACTION

APACs have a number of important and unique properties. The compounds are named after their unique dual antiplatelet (AP) and anticoagulant (AC) activity. They uniquely target vascular injury sites where they provide local long-term antithrombotic and anti-inflammatory action without a prolonged systemic effect. Among other benefits, this profile is anticipated to lead to a reduced bleeding risk compared with systemically acting antithrombotics.

OUR COMPANY

Aplagon was established to translate proprietary scientific discoveries on APACs from bench to bedside. The Company is supported by an experienced management team and Board, an excellent scientific network, and backed by a strong syndicate of leading Finnish investors.

Watch our video to learn more about our first-in-class APACs

CLINICAL DEVELOPMENT PARTNERSHIP

Aplagon is partnered with Cadila Pharmaceuticals for the clinical development and commercialization of its lead APAC product in India. Aplagon retains all rights outside India.